Table 4.
Antibiotic susceptibility profiles of S. aureus strains isolated from clinical specimens by disk diffusion method.
| Antibiotic | MSSA (N = 22), n (%) |
MRSA (N = 19), n (%) |
||||
|---|---|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | |
| Vancomycina | 22 (100) | - | - | 19 (100) | - | - |
| Penicillin | 6 (27.2) | - | 16 (72.7) | - | - | 19 (100) |
| Co-amoxiclav | 10 (45.4) | - | 12 (54.5) | 2 (10.5) | - | 17 (89.4) |
| Chloramphenicol | 22 (100) | - | - | - | - | 19 (100) |
| Tetracycline | 20 (90.9) | - | 2 (9) | 3 (15.7) | 16 (84.2) | |
| Ciprofloxacin | 22 (100) | - | - | 1 (5.2) | 5 (26.3) | 13 (68.4) |
| Ceftriaxone | 16 (72.7) | 6 (27.2) | - | 2 (10.5) | - | 17 (89.4) |
| Cefazolin | 21 (95.4) | - | 1 (4.5) | 3 (15.7) | 1 (5.2) | 15 (78.9) |
| Clindamycin | 20 (90.9) | - | 2 (9) | 1 (5.2) | - | 18 (94.7) |
| Imipenem | 22 (100) | - | - | 14 (73.6) | 3 (15.7) | 2 (10.5) |
| Co-trimoxazole | 18 (81.8) | 1 (4.5) | 3 (13.6) | 17 (89.4) | - | 2 (10.5) |
| Erythromycin | 20 (90.9) | - | 2 (9) | 3 (15.7) | - | 16 (84.2) |
| Gentamicin | 22 (100) | - | - | 4 (21) | - | 15 (78.9) |
| Rifampicin | 22 (100) | - | - | 3 (15.7) | - | 16 (84.2) |
| Pristinamycin | 18 (81.8) | 1 (4.5) | 3 (13.6) | 5 (26.3) | - | 14 (73.6) |
| Linezolid | 22 (100) | - | - | 19 (100) | - | - |
| Mupirocin | 22 (100) | - | - | 19 (100) | - | - |
a
Vancomycin susceptibility profile was determined using agar dilution method.